ReviewCurrent treatment options in cardiovascular medicine2016
Direct Cardiac Cellular Reprogramming for Cardiac Regeneration.
Review in Current treatment options in cardiovascular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Sall4 and Gata4 induce cardiac fibroblast transition towards a partially multipotent state with cardiogenic potential.Scientific reports · 2024Article
- p63 silencing induces epigenetic modulation to enhance human cardiac fibroblast to cardiomyocyte-like differentiation.Scientific reports · 2022Article
- Hippo Pathway Effector Tead1 Induces Cardiac Fibroblast to Cardiomyocyte Reprogramming.Journal of the American Heart Association · 2021Article
- Commentary: Evidence-based human stem cell therapy for myocardial healing: Miles to go.JTCVS open · 2021Article
- Bioengineering Technologies for Cardiac Regenerative Medicine.Frontiers in bioengineering and biotechnology · 2021Review
- Enhanced Generation of Induced Cardiomyocytes Using a Small-Molecule Cocktail to Overcome Barriers to Cardiac Cellular Reprogramming.Journal of the American Heart Association · 2020Article
- Commentary: Doubling down on adeno-associated viruses for cardiac gene therapy.The Journal of thoracic and cardiovascular surgery · 2020Article
- Polycomb Repressive Complex 2 Proteins EZH1 and EZH2 Regulate Timing of Postnatal Hepatocyte Maturation and Fibrosis by Repressing Genes With Euchromatic Promoters in Mice.Gastroenterology · 2019Article
- Cardiac-mimetic cell-culture system for direct cardiac reprogramming.Theranostics · 2019Article
- Molecular discoveries and treatment strategies by direct reprogramming in cardiac regeneration.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Modulating Cell Fate as a Therapeutic Strategy.Cell stem cell · 2018Review
- Cardiac stem cell trials and the new world of cellular reprogramming: Time to move on.The Journal of thoracic and cardiovascular surgery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
opinion statementDirect cardiac cellular reprogramming of endogenous cardiac fibroblasts directly into induced cardiomyocytes is a highly feasible, promising therapeutic option for patients with advanced heart failure. The most successful cardiac reprogramming strategy will likely be a multimodal approach involving an optimal combination of cardio-differentiating factors, suppression of fibroblast gene expression, and induction of angiogenic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.